SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...
The Argus II, a “bionic eye”, is intended to provide electrical stimulation of the retina to elicit visual perception in blind subjects with severe to profound retinitis pigmentosa, according to the ...
Argus II is a novel healthcare technology that restores vision in RP patients. Improvements in visual acuity are expected to lead to improvements in patient self-confidence, decreasing their ...
SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...
A new final guidance document published by the US Food and Drug Administration (FDA) recommends to sponsors methods of conducting clinical research in support of investigational medical device ...
University Hospitals Eye Institute in Cleveland has announced that it will begin offering patients the Argus II Retinal Prosthesis System, a “bionic eye” designed to treat late stage retinitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results